NKG2A/CD94 recombinant antibody

Anti-NKG2A/CD94 Reference Antibody (monalizumab)

Cat. Num. AAA297097

• Gene Names: KLRC1; NKG2; NKG2A; CD159A
• Reactivity: Baboon, Human
• Applications: Flow Cytometry
• Synonyms: NKG2A/CD94, Recombinant Antibody; Anti-NKG2A/CD94 Reference Antibody (monalizumab); NKG2A/CD94 recombinant antibody

• Host: CHO Cell
• Reactivity: Baboon, Human
• Clonality: Monoclonal
• Isotype: IgG4
• Specificity: NKG2A/CD94
• Form/Format: Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

• Applicable Applications for NKG2A/CD94 recombinant antibody: FCM (Flow Cytometry), Kinetics, Animal Model
• Endotoxin: < 0.001EU/ug, determined by LAL method.
• Conjugation: Unconjugated
• Dry Ice Note: The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
• Preparation and Storage: Store at -20C in small aliquots to prevent freeze-thaw cycles.

Application Data

(Anti-NKG2A / CD159a Reference Antibody (monalizumab) Luciferase Assay was evaluated using Human NKG2A/CD94 HEK293. The EC50 was approximately 0.5236 nM.)

FCM/FACS (Flow Cytometry)

(Anti-NKG2A / CD159a Reference Antibody (monalizumab) FACS Blocking was evaluated using human NKG2A/CD94 HEK293 cells. The IC50 was approximately 0.2162 nM.)

FCM/FACS (Flow Cytometry)

(Human NKG2A/CD94 HEK293 cells were stained with Anti-NKG2A / CD94 Reference Antibody (monalizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC480=0.0409 ug/mL)

Application Data

(The purity of Anti-NKG2A / CD94 Reference Antibody (monalizumab)is more than 95% ,determined by SEC-HPLC.)

SDS-PAGE

(Anti-NKG2A / CD94 Reference Antibody (monalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%)

Related Product Information for NKG2A/CD94 recombinant antibody

Function: Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self (PubMed:18083576, PubMed:37264229, PubMed:9430220, PubMed:9486650). Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules (PubMed:12165520, PubMed:9485206). Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed:30860984, PubMed:9430220, PubMed:9485206, PubMed:9486650). Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742). On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens (PubMed:18064301). In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion (PubMed:30503213, PubMed:30860984).

Cellular Location: Cell membrane; Single-pass type II membrane protein

Tissue Location: Predominantly expressed in NK cells (at protein level) (PubMed:20952657, PubMed:9430220, PubMed:9485206). Expressed in intraepithelial CD8-positive T cell subsets with higher frequency in gamma-delta T cells than alpha-beta T cells (at protein level) (PubMed:18064301). Expressed in memory gamma-delta T cells (at protein level) (PubMed:20952657). Restricted to a subset of memory/effector CD8-positive alpha-beta T cells (at protein level) (PubMed:12387742) Expressed in intratumoral NK and CD8-positive T cells (PubMed:30503213). Expressed in melanoma-specific cytotoxic T cell clones (at protein level) (PubMed:9485206). KLRD1-KLRC1 and KLRD1-KLRC2 are differentially expressed in NK and T cell populations, with only minor subsets expressing both receptor complexes (at protein level) (PubMed:20952657).

Product Categories/Family for NKG2A/CD94 recombinant antibody

Primary Antibodies

NCBI and Uniprot Product Information

• NCBI GI #: 4504881
• NCBI GeneID: 3821
• NCBI Accession #: NP_002250.1
• NCBI GenBank Nucleotide #: NM_002259.4
• UniProt Accession #: P26715
• Molecular Weight: 145 KDa
• NCBI Official Full Name: NKG2-A/NKG2-B type II integral membrane protein isoform NKG2-A
• NCBI Official Synonym Full Names: killer cell lectin-like receptor subfamily C, member 1
• NCBI Official Symbol: KLRC1
• NCBI Official Synonym Symbols: NKG2; NKG2A; CD159A
• NCBI Protein Information: NKG2-A/NKG2-B type II integral membrane protein; NK cell receptor A; C-lectin type II protein; natural killer cell lectin; natural killer group protein 2; NKG2-1/B activating NK receptor; NKG2-A/B-activating NK receptor; CD159 antigen-like family member A
• UniProt Protein Name: NKG2-A/NKG2-B type II integral membrane protein
• UniProt Gene Name: KLRC1
• UniProt Synonym Gene Names: NKG2A
• UniProt Entry Name: NKG2A_HUMAN